首页 > 最新文献

ARP Rheumatology最新文献

英文 中文
FRAX 10-year fracture risk in rheumatoid arthritis assessed with and without bone mineral density - are we treating our patients under bDMARDs? FRAX类风湿性关节炎患者10年骨折风险评估有无骨密度-我们是否在bDMARDs下治疗我们的患者?
4区 医学 Q3 RHEUMATOLOGY Pub Date : 2023-01-01
Maria Seabra Rato, Filipe Oliveira Pinheiro, Salomé Garcia, Bruno Fernandes, Alexandra Bernardo, Rita Gaio, Lúcia Costa, Miguel Bernardes

Objective: This study aimed to identify the rheumatoid arthritis (RA) patients under biological therapy who have FRAX® scores classified as high fracture risk and to evaluate if they are receiving treatment for osteoporosis (OP). The authors also investigated the intra-individual agreement between FRAX® fracture risk calculated with and without bone mineral density (BMD).

Methods: A single-center retrospective cohort study was performed in a total of 303 patients with RA under biologics. Demographic and clinical data were collected using Rheumatic Diseases Portuguese Register (Reuma.pt), complemented with data from the hospital clinical records. FRAX scores with and without BMD were calculated. The Kendall's Tau coefficient was used to assess the agreement between FRAX risk categories. Correlations were evaluated by the Spearman test. Comparisons of distributions from independent variables used the Mann-Whitney test.

Results: When FRAX® score was calculated without BMD (n=303), 25% patients were categorized as high fracture risk. Among them, only 54% were receiving OP treatment. FRAX® assessment with BMD (n=231) identified 33% patients with high fracture risk, 52% in treatment for OP. Thirty patients (21%) previously classified as low fracture risk using FRAX® without BMD were recategorized as high risk (𝜏=0.570, p.

目的:本研究旨在识别FRAX评分为高骨折风险的类风湿性关节炎(RA)患者,并评估他们是否正在接受骨质疏松症(OP)治疗。作者还研究了考虑和不考虑骨密度(BMD)的FRAX®骨折风险之间的个体内一致性。方法:采用单中心回顾性队列研究,共纳入303例接受生物制剂治疗的RA患者。使用葡萄牙风湿病登记册(Reuma.pt)收集人口统计和临床数据,并辅以医院临床记录的数据。计算有无骨密度的FRAX评分。Kendall's Tau系数用于评估FRAX风险类别之间的一致性。通过Spearman检验评估相关性。自变量分布的比较采用Mann-Whitney检验。结果:在没有骨密度的情况下计算FRAX评分时(n=303), 25%的患者被归为高骨折风险。其中,接受OP治疗的仅占54%。FRAX®骨密度评估(n=231)发现33%的患者骨折风险高,52%的患者骨折风险高。30例(21%)先前使用FRAX®无骨密度评估为低骨折风险的患者被重新划分为高风险(平均水平为0.570,p。
{"title":"FRAX 10-year fracture risk in rheumatoid arthritis assessed with and without bone mineral density - are we treating our patients under bDMARDs?","authors":"Maria Seabra Rato,&nbsp;Filipe Oliveira Pinheiro,&nbsp;Salomé Garcia,&nbsp;Bruno Fernandes,&nbsp;Alexandra Bernardo,&nbsp;Rita Gaio,&nbsp;Lúcia Costa,&nbsp;Miguel Bernardes","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to identify the rheumatoid arthritis (RA) patients under biological therapy who have FRAX® scores classified as high fracture risk and to evaluate if they are receiving treatment for osteoporosis (OP). The authors also investigated the intra-individual agreement between FRAX® fracture risk calculated with and without bone mineral density (BMD).</p><p><strong>Methods: </strong>A single-center retrospective cohort study was performed in a total of 303 patients with RA under biologics. Demographic and clinical data were collected using Rheumatic Diseases Portuguese Register (Reuma.pt), complemented with data from the hospital clinical records. FRAX scores with and without BMD were calculated. The Kendall's Tau coefficient was used to assess the agreement between FRAX risk categories. Correlations were evaluated by the Spearman test. Comparisons of distributions from independent variables used the Mann-Whitney test.</p><p><strong>Results: </strong>When FRAX® score was calculated without BMD (n=303), 25% patients were categorized as high fracture risk. Among them, only 54% were receiving OP treatment. FRAX® assessment with BMD (n=231) identified 33% patients with high fracture risk, 52% in treatment for OP. Thirty patients (21%) previously classified as low fracture risk using FRAX® without BMD were recategorized as high risk (𝜏=0.570, p.</p>","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 1","pages":"47-52"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9343613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parameniscal cyst: an important differential diagnosis in slow growing masses of the knee. 骨膜旁囊肿:一个重要的鉴别诊断在缓慢增长的肿块的膝盖。
4区 医学 Q3 RHEUMATOLOGY Pub Date : 2023-01-01
Liliana Saraiva, André Pinto Saraiva, Margarida Coutinho, José António Pereira da Silva

Introduction: Parameniscal cysts are small cystic lesions, near the meniscus, involving medial and lateral compartments at equal frequency. Frequently, parameniscal cysts are so small that patients do not notice them, being asymptomatic. However, they can grow and exceed 2 centimeters in diameter, causing pain and alarm due to the slow growing mass. Magnetic Resonance Imaging (MRI) is the gold standard for diagnosis.

Methods: Case report of a patient admitted to rheumatology department in the Centro Hospitalar e Universitário de Coimbra.

Results: We report a case of a 47-year-old male with idiopathic juvenile arthritis, who presented with a slow-growing mass over the medial aspect of the right knee. MRI revealed a conspicuous cystic ovoid lesion, compatible with a parameniscal cyst, associated with structural heterogeneity of the posterior edge of the internal meniscus with a longitudinal fracture at this level.

Conclusion: This is the first case of parameniscal cyst reported in patients with inflammatory rheumatic disease and the differential diagnosis with synovial cyst, baker cyst, ganglion cyst, bursitis, hematoma and neoplasms is of utmost importance.

腹膜旁囊肿是半月板附近的小囊性病变,累及内侧和外侧腔室的频率相同。通常情况下,乳突囊肿很小,患者没有注意到它们,没有症状。然而,它们可以生长,直径超过2厘米,由于生长缓慢,会引起疼痛和警报。磁共振成像(MRI)是诊断的金标准。方法:对Universitário科英布拉中心医院风湿病科收治的1例患者进行病例报告。结果:我们报告一例47岁男性特发性幼年关节炎,谁提出了一个缓慢增长的肿块在右膝内侧。MRI显示一个明显的囊性卵形病变,与腹膜旁囊肿相符,与内半月板后缘结构不均匀相关,并在这一水平发生纵向骨折。结论:本病例为炎症性风湿病患者中首次报道的滑膜囊肿、贝克囊肿、神经节囊肿、滑囊炎、血肿及肿瘤的鉴别诊断至关重要。
{"title":"Parameniscal cyst: an important differential diagnosis in slow growing masses of the knee.","authors":"Liliana Saraiva,&nbsp;André Pinto Saraiva,&nbsp;Margarida Coutinho,&nbsp;José António Pereira da Silva","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Parameniscal cysts are small cystic lesions, near the meniscus, involving medial and lateral compartments at equal frequency. Frequently, parameniscal cysts are so small that patients do not notice them, being asymptomatic. However, they can grow and exceed 2 centimeters in diameter, causing pain and alarm due to the slow growing mass. Magnetic Resonance Imaging (MRI) is the gold standard for diagnosis.</p><p><strong>Methods: </strong>Case report of a patient admitted to rheumatology department in the Centro Hospitalar e Universitário de Coimbra.</p><p><strong>Results: </strong>We report a case of a 47-year-old male with idiopathic juvenile arthritis, who presented with a slow-growing mass over the medial aspect of the right knee. MRI revealed a conspicuous cystic ovoid lesion, compatible with a parameniscal cyst, associated with structural heterogeneity of the posterior edge of the internal meniscus with a longitudinal fracture at this level.</p><p><strong>Conclusion: </strong>This is the first case of parameniscal cyst reported in patients with inflammatory rheumatic disease and the differential diagnosis with synovial cyst, baker cyst, ganglion cyst, bursitis, hematoma and neoplasms is of utmost importance.</p>","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 1","pages":"83-84"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9344062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of biologic therapies on risk of adverse cardiovascular events in patients with Ankylosing Spondylitis or Psoriatic Arthritis: A systematic literature review. 生物疗法对强直性脊柱炎或银屑病关节炎患者不良心血管事件风险的影响:系统文献综述
4区 医学 Q3 RHEUMATOLOGY Pub Date : 2023-01-01
Konstantina Samira Magiouf, Kalliopi Fragiadaki, Adrianni Charpidou, Alexandros Syrigos, Elias Kotteas, Georgia Kourlaba

Background: Recent evidence highlights increased mortality and morbidity due to cardiovascular disease (CVD), especially within the two major forms of Spondyloarthropathies (SpAs), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA). Healthcare professionals and patients in these populations should be alerted regarding the high risk of cardiovascular (CV) events and thus, customize the treatment strategy accordingly.

Objective: This systematic literature review aimed to determine the effects of biological therapies on serious CV events in AS and PsA.

Methods: Screening for the study was carried out using PubMed and Scopus databases from the database's inception to the 17th of July 2021. The literature search strategy for this review is based on the Population, Intervention, Comparator, Outcomes (PICOs) framework. Randomized controlled trials (RCTs) of biologic therapies for the treatment of AS and/or PsA were included. The primary outcome measure was the number of serious CV events reported during the placebo-controlled phase.

Results: 4,422 articles were generated from keywords, eligibility criteria, and databases. Following the screening, we retained 13 studies for analysis: 3 in AS and 10 in PsA. Meta-analysis of results was not feasible due to the small number of the identified studies, the heterogeneity of the biologic treatment and the included populations, as well as the infrequently reported requested endpoint. According to our review, biologic treatments are safe options as for CV risk in patients with PsA or AS.

Conclusion: Further and more extensive trials in AS/PsA patients at high risk of CV events are needed before firm conclusions can be drawn.

背景:最近的证据强调心血管疾病(CVD)导致的死亡率和发病率增加,特别是在两种主要形式的脊椎关节病(spa)中,强直性脊柱炎(AS)和银屑病关节炎(PsA)。这些人群中的医疗保健专业人员和患者应该警惕心血管(CV)事件的高风险,从而相应地定制治疗策略。目的:本系统文献综述旨在确定生物疗法对AS和PsA严重心血管事件的影响。方法:从PubMed和Scopus数据库建立至2021年7月17日,对该研究进行筛选。本综述的文献检索策略基于人群、干预、比较者、结果(PICOs)框架。纳入了生物疗法治疗AS和/或PsA的随机对照试验(rct)。主要结局指标是在安慰剂对照期报告的严重心血管事件的数量。结果:从关键词、资格标准和数据库中生成了4,422篇文章。在筛选之后,我们保留了13项研究进行分析:3项关于AS, 10项关于PsA。由于确定的研究数量少,生物治疗和纳入人群的异质性,以及很少报告要求的终点,结果的荟萃分析是不可行的。根据我们的综述,对于PsA或as患者的心血管风险,生物治疗是安全的选择。结论:在得出确切的结论之前,需要对心血管事件高风险的AS/PsA患者进行进一步和更广泛的试验。
{"title":"Impact of biologic therapies on risk of adverse cardiovascular events in patients with Ankylosing Spondylitis or Psoriatic Arthritis: A systematic literature review.","authors":"Konstantina Samira Magiouf,&nbsp;Kalliopi Fragiadaki,&nbsp;Adrianni Charpidou,&nbsp;Alexandros Syrigos,&nbsp;Elias Kotteas,&nbsp;Georgia Kourlaba","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Recent evidence highlights increased mortality and morbidity due to cardiovascular disease (CVD), especially within the two major forms of Spondyloarthropathies (SpAs), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA). Healthcare professionals and patients in these populations should be alerted regarding the high risk of cardiovascular (CV) events and thus, customize the treatment strategy accordingly.</p><p><strong>Objective: </strong>This systematic literature review aimed to determine the effects of biological therapies on serious CV events in AS and PsA.</p><p><strong>Methods: </strong>Screening for the study was carried out using PubMed and Scopus databases from the database's inception to the 17th of July 2021. The literature search strategy for this review is based on the Population, Intervention, Comparator, Outcomes (PICOs) framework. Randomized controlled trials (RCTs) of biologic therapies for the treatment of AS and/or PsA were included. The primary outcome measure was the number of serious CV events reported during the placebo-controlled phase.</p><p><strong>Results: </strong>4,422 articles were generated from keywords, eligibility criteria, and databases. Following the screening, we retained 13 studies for analysis: 3 in AS and 10 in PsA. Meta-analysis of results was not feasible due to the small number of the identified studies, the heterogeneity of the biologic treatment and the included populations, as well as the infrequently reported requested endpoint. According to our review, biologic treatments are safe options as for CV risk in patients with PsA or AS.</p><p><strong>Conclusion: </strong>Further and more extensive trials in AS/PsA patients at high risk of CV events are needed before firm conclusions can be drawn.</p>","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 1","pages":"53-63"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9354612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of undiagnosed rheumatic and musculoskeletal diseases and its association with health-related quality of life and with physical function. 未确诊的风湿病和肌肉骨骼疾病的患病率及其与健康相关的生活质量和身体功能的关系
4区 医学 Q3 RHEUMATOLOGY Pub Date : 2023-01-01
Nuno Pina Gonçalves, Sofia Azeredo, Alexandre Sepriano, Ana Rita Henriques, Tomás Pires, Jaime C Branco, Helena Canhão, Ana M Rodrigues

Aim: To estimate the disease specific prevalence of undiagnosed rheumatic and musculoskeletal diseases (RMDs) in Portugal and determine if people with undiagnosed RMDs have worse quality of life, physical function and higher health resources consumption, than people without RMDs.

Methods: A subgroup analysis of EpiReumaPt was made that included all participants≥18 years evaluated by a rheumatologist. Participants were stratified into three groups: undiagnosed RMDs; previously diagnosed RMDs; non-RMDs. A descriptive analysis of the three groups was performed. To estimate the prevalence of undiagnosed RMDs, weighted proportion were computed considering the sample design. The three groups were compared (Undiagnosed RMDs vs non-RMDs; Previously diagnosed RMDs vs non-RMDs) for health related quality of life (HRQoL) (EQ5D), physical function (HAQ), mental health (HADS) and health resources consumption. The effect of being undiagnosed for these outcomes was assessed in multivariable models adjusted for age, gender, geographical region and years of education (reference: non-RMD).

Results: A total of 3877 participants were included. The prevalence of undiagnosed RMDs was 29%. Compared to participants without RMDs, undiagnosed participants had lower HRQoL (EQ-5D: β (95% CI)=-0.07 (-0.103,-0.043)) and physical function (HAQ: β (95% CI)=0.10 (0.05, 0.15)), more anxiety (OR (95% CI)=2.3 (1.4, 3.7)) and depression symptoms (OR (95% CI)=1.4 (0.8, 2.4)). Undiagnosed RMDs participants were more likely to visit an orthopedist (OR (95% CI)=2.0 (1.1, 3.5)) and had a higher number of orthopedic appointments (IRR (95% CI)=2.5 (1.3, 4.9)) than participants without RMDs.

Conclusion: Patients with undiagnosed RMDs are frequent in Portugal, have worse HRQoL, physical function and mental health than people without RMDs. Undiagnosed patients are nonetheless consumers of health resources and tend to seek help from specialties other than rheumatology. Increasing the awareness of RMDs might promote their early identification and treatment leading to both personal and societal benefits.

目的:估计葡萄牙未确诊的风湿病和肌肉骨骼疾病(RMDs)的疾病特异性患病率,并确定未确诊的RMDs患者是否比未确诊的RMDs患者的生活质量、身体功能和卫生资源消耗更差。方法:对EpiReumaPt进行亚组分析,纳入由风湿病学家评估的所有≥18岁的参与者。参与者被分为三组:未确诊的rmd;先前诊断的rmd;non-RMDs。对三组患者进行描述性分析。为了估计未确诊rmd的患病率,考虑到样本设计,计算加权比例。对三组进行比较(未诊断的rmd与非rmd;在健康相关生活质量(HRQoL) (EQ5D)、身体功能(HAQ)、心理健康(HADS)和卫生资源消耗方面,先前诊断为rmd与非rmd的患者。未确诊对这些结果的影响在调整了年龄、性别、地理区域和教育年限的多变量模型中进行了评估(参考文献:非rmd)。结果:共纳入3877名受试者。未确诊的rmd患病率为29%。与没有RMDs的参与者相比,未确诊的参与者HRQoL (EQ-5D: β (95% CI)=-0.07(-0.103,-0.043))和身体功能(HAQ: β (95% CI)=0.10(0.05, 0.15))更低,焦虑(OR (95% CI)=2.3(1.4, 3.7))和抑郁症状(OR (95% CI)=1.4(0.8, 2.4))更多。与没有rmd的参与者相比,未确诊的rmd参与者更有可能去看骨科医生(OR (95% CI)=2.0(1.1, 3.5)),并且有更多的骨科预约(IRR (95% CI)=2.5(1.3, 4.9))。结论:在葡萄牙,未确诊的RMDs患者较为常见,其HRQoL、生理功能和心理健康状况均较无RMDs者差。尽管如此,未确诊的患者仍然是卫生资源的消费者,并且倾向于向风湿病学以外的其他专业寻求帮助。提高对rmd的认识可能会促进其早期识别和治疗,从而为个人和社会带来好处。
{"title":"Prevalence of undiagnosed rheumatic and musculoskeletal diseases and its association with health-related quality of life and with physical function.","authors":"Nuno Pina Gonçalves,&nbsp;Sofia Azeredo,&nbsp;Alexandre Sepriano,&nbsp;Ana Rita Henriques,&nbsp;Tomás Pires,&nbsp;Jaime C Branco,&nbsp;Helena Canhão,&nbsp;Ana M Rodrigues","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Aim: </strong>To estimate the disease specific prevalence of undiagnosed rheumatic and musculoskeletal diseases (RMDs) in Portugal and determine if people with undiagnosed RMDs have worse quality of life, physical function and higher health resources consumption, than people without RMDs.</p><p><strong>Methods: </strong>A subgroup analysis of EpiReumaPt was made that included all participants≥18 years evaluated by a rheumatologist. Participants were stratified into three groups: undiagnosed RMDs; previously diagnosed RMDs; non-RMDs. A descriptive analysis of the three groups was performed. To estimate the prevalence of undiagnosed RMDs, weighted proportion were computed considering the sample design. The three groups were compared (Undiagnosed RMDs vs non-RMDs; Previously diagnosed RMDs vs non-RMDs) for health related quality of life (HRQoL) (EQ5D), physical function (HAQ), mental health (HADS) and health resources consumption. The effect of being undiagnosed for these outcomes was assessed in multivariable models adjusted for age, gender, geographical region and years of education (reference: non-RMD).</p><p><strong>Results: </strong>A total of 3877 participants were included. The prevalence of undiagnosed RMDs was 29%. Compared to participants without RMDs, undiagnosed participants had lower HRQoL (EQ-5D: β (95% CI)=-0.07 (-0.103,-0.043)) and physical function (HAQ: β (95% CI)=0.10 (0.05, 0.15)), more anxiety (OR (95% CI)=2.3 (1.4, 3.7)) and depression symptoms (OR (95% CI)=1.4 (0.8, 2.4)). Undiagnosed RMDs participants were more likely to visit an orthopedist (OR (95% CI)=2.0 (1.1, 3.5)) and had a higher number of orthopedic appointments (IRR (95% CI)=2.5 (1.3, 4.9)) than participants without RMDs.</p><p><strong>Conclusion: </strong>Patients with undiagnosed RMDs are frequent in Portugal, have worse HRQoL, physical function and mental health than people without RMDs. Undiagnosed patients are nonetheless consumers of health resources and tend to seek help from specialties other than rheumatology. Increasing the awareness of RMDs might promote their early identification and treatment leading to both personal and societal benefits.</p>","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 1","pages":"7-16"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9343612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Demographic and clinical features of pediatric vasculitis: a single-center study. 儿童血管炎的人口统计学和临床特征:一项单中心研究。
4区 医学 Q3 RHEUMATOLOGY Pub Date : 2023-01-01
Tiago Santos Trindade, Catarina Granjo Morais, Ana Maia, Mariana Rodrigues, Iva Brito

Introduction: Vasculitides are rare systemic conditions which may occur in childhood. This study aims to document demographic and clinical features of systemic vasculitides in a tertiary center, comparing our outcomes with previously published studies of other international centers.

Methods: Patients presenting with systemic vasculitis before 18 years of age, admitted to a tertiary Portuguese center at diagnosis or during follow-up, from 2009 to 2020, were retrospectively included in this study.

Results: In our study, we included 138 patients. The youngest patients at diagnosis were in the Kawasaki's disease (KD) group, with a median age at diagnosis of 2.26 years old (IQR 1.07-6.20), as opposed to the Behçet's syndrome (BS) group with a median age at diagnosis of 13.41 years old (IQR 10.19-16.75), which was significantly higher (p 90% in both IgA Vasculitis (IgAV) and KD. Gastrointestinal symptoms were common in all groups (15-50%), rarer in BS (17%). Arthritis and arthralgia were highly prevalent in IgAV (65%). The American Heart Association criteria of diagnosis for complete KD were met in 62% of cases. No significant difference was found in age distribution between complete and incomplete diagnosis (p=0.616). Mean duration of fever in KD was 9.6 ±2.1 days, which was higher than anticipated. Renal manifestations in IgAV (11%) and ophthalmic involvement in BS (22%) were lower than expected. There was a notable number of children reporting joint involvement in KD (27%). We also noticed a slightly higher prevalence of vascular events in BS (30%).

Conclusions: Each specific vasculitis assessed had different key symptoms, but there are several complaints and signs shown by our patients, some of them overlapping between vasculitides and others very atypical, such as recurrent epididymitis in BS due to microvasculitis. We can state that most of our findings are in concordance with current literature, with some notable exceptions. Pediatric multicentric population-based studies are warranted to increase research and design clinical trials concerning this field of knowledge.

血管性疾病是一种罕见的全身性疾病,可能发生在儿童时期。本研究旨在记录一个三级中心的全身性血管病的人口学和临床特征,并将我们的结果与其他国际中心先前发表的研究结果进行比较。方法:从2009年到2020年,18岁前出现全身性血管炎的患者,在诊断或随访期间入住葡萄牙三级中心,回顾性纳入本研究。结果:在我们的研究中,我们纳入138例患者。诊断时最年轻的患者为川崎病(KD)组,诊断时中位年龄为2.26岁(IQR 1.07-6.20),而behet综合征(BS)组诊断时中位年龄为13.41岁(IQR 10.19-16.75), IgA血管炎(IgAV)和KD的中位年龄均显著高于川崎病(IQR 10.19-16.75) (p < 90%)。胃肠道症状在所有组中都很常见(15-50%),BS组较少见(17%)。关节炎和关节痛在IgAV中非常普遍(65%)。62%的病例符合美国心脏协会诊断完全KD的标准。完全诊断与不完全诊断的年龄分布差异无统计学意义(p=0.616)。患者平均发热时间9.6±2.1 d,高于预期。IgAV患者的肾脏表现(11%)和BS患者的眼部受累(22%)低于预期。有显著数量的儿童报告共同参与KD(27%)。我们还注意到BS中血管事件的发生率略高(30%)。结论:评估的每种特定血管炎有不同的关键症状,但我们的患者有几种主诉和体征,其中一些与血管炎重叠,另一些非常不典型,如BS患者因微血管炎引起的复发性附睾炎。我们可以说,我们的大多数发现都与当前的文献一致,但也有一些明显的例外。儿科多中心人群为基础的研究是必要的,以增加研究和设计有关这一知识领域的临床试验。
{"title":"Demographic and clinical features of pediatric vasculitis: a single-center study.","authors":"Tiago Santos Trindade,&nbsp;Catarina Granjo Morais,&nbsp;Ana Maia,&nbsp;Mariana Rodrigues,&nbsp;Iva Brito","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Vasculitides are rare systemic conditions which may occur in childhood. This study aims to document demographic and clinical features of systemic vasculitides in a tertiary center, comparing our outcomes with previously published studies of other international centers.</p><p><strong>Methods: </strong>Patients presenting with systemic vasculitis before 18 years of age, admitted to a tertiary Portuguese center at diagnosis or during follow-up, from 2009 to 2020, were retrospectively included in this study.</p><p><strong>Results: </strong>In our study, we included 138 patients. The youngest patients at diagnosis were in the Kawasaki's disease (KD) group, with a median age at diagnosis of 2.26 years old (IQR 1.07-6.20), as opposed to the Behçet's syndrome (BS) group with a median age at diagnosis of 13.41 years old (IQR 10.19-16.75), which was significantly higher (p 90% in both IgA Vasculitis (IgAV) and KD. Gastrointestinal symptoms were common in all groups (15-50%), rarer in BS (17%). Arthritis and arthralgia were highly prevalent in IgAV (65%). The American Heart Association criteria of diagnosis for complete KD were met in 62% of cases. No significant difference was found in age distribution between complete and incomplete diagnosis (p=0.616). Mean duration of fever in KD was 9.6 ±2.1 days, which was higher than anticipated. Renal manifestations in IgAV (11%) and ophthalmic involvement in BS (22%) were lower than expected. There was a notable number of children reporting joint involvement in KD (27%). We also noticed a slightly higher prevalence of vascular events in BS (30%).</p><p><strong>Conclusions: </strong>Each specific vasculitis assessed had different key symptoms, but there are several complaints and signs shown by our patients, some of them overlapping between vasculitides and others very atypical, such as recurrent epididymitis in BS due to microvasculitis. We can state that most of our findings are in concordance with current literature, with some notable exceptions. Pediatric multicentric population-based studies are warranted to increase research and design clinical trials concerning this field of knowledge.</p>","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 1","pages":"30-40"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9343616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare association of cryoglobulinaemic vasculitis and granulomatosis with polyangiitis treated with a short course of glucocorticoids combined with cyclophosphamide and rituximab. 低温球蛋白贫血性血管炎和肉芽肿病与多血管炎的罕见关联,短期糖皮质激素联合环磷酰胺和利妥昔单抗治疗。
4区 医学 Q3 RHEUMATOLOGY Pub Date : 2023-01-01
Augusto Silva, Cláudia Costa, Iolanda Godinho, Sofia Jorge, Lurdes Correia, João Boavida, Pedro Vasconcelos, Rita Theias, João Janeiro, João Inácio, José António Lopes, José Carlos Romeu, João Eurico Fonseca, Cristina Ponte, Estela Nogueira
{"title":"A rare association of cryoglobulinaemic vasculitis and granulomatosis with polyangiitis treated with a short course of glucocorticoids combined with cyclophosphamide and rituximab.","authors":"Augusto Silva,&nbsp;Cláudia Costa,&nbsp;Iolanda Godinho,&nbsp;Sofia Jorge,&nbsp;Lurdes Correia,&nbsp;João Boavida,&nbsp;Pedro Vasconcelos,&nbsp;Rita Theias,&nbsp;João Janeiro,&nbsp;João Inácio,&nbsp;José António Lopes,&nbsp;José Carlos Romeu,&nbsp;João Eurico Fonseca,&nbsp;Cristina Ponte,&nbsp;Estela Nogueira","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 1","pages":"85-87"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9797522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety data from the use of antifibrotics in connective tissue disease-related interstitial lung disease: particular emphasis on association with immunosuppression. 使用抗纤维化药物治疗结缔组织病相关间质性肺疾病的安全性数据:特别强调与免疫抑制的关联
4区 医学 Q3 RHEUMATOLOGY Pub Date : 2023-01-01
Ana Catarina Duarte, Ana Cordeiro, Miguel Lopes, Jorge Soares, Maria José Santos
{"title":"Safety data from the use of antifibrotics in connective tissue disease-related interstitial lung disease: particular emphasis on association with immunosuppression.","authors":"Ana Catarina Duarte,&nbsp;Ana Cordeiro,&nbsp;Miguel Lopes,&nbsp;Jorge Soares,&nbsp;Maria José Santos","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 1","pages":"88-91"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9814918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rheumatoid arthritis monotherapy in the Jak inhibitors Era. Current prevalence and associated factors in a multicenter study. Jak抑制剂时代的类风湿性关节炎单药治疗。一项多中心研究的当前患病率及相关因素。
4区 医学 Q3 RHEUMATOLOGY Pub Date : 2023-01-01
Rodrigo Garcia-Salinas, Fernando Sommerfleck, Alfredo Vargas-Caselles, Luis Palomino-Romero, Javier Rosa, Mariana Benegas, Etel Saturansky, Pamela Giorgis, Florencia Martinez, Marcelo Abdala, Jimene Sanchez-Alcover, Emma Civit, Vanesa Espasa, Veronica Bellomio, Juan Manuel Bande, Silvia Papasidero, Veronica Saurit, Leticia Ibañez-Zurlo, Emilio Buschiazzo

Background: Combined therapy constitutes the standard of care in RA. Jak inhibitors (Jaki) have shown efficacy in monotherapy, a modality used in cases where it is not possible to use Disease-Modifying Anti Rheumatic Drugs (csDMARDs).

Objectives: To estimate the prevalence (total and by drug), reason for using and the increase over the time of bDMARDs or tsDMARDs as monotherapy after the availability of the Jaki. To analyze the differential characteristics between patients with monotherapy vs combined therapy.

Methods: Cross-sectional multicenter study. Consecutive patients with a diagnosis of RA (ACR/EULAR 2010) under treatment with bDMARDs or tsDMARDs started from 2013 were included. Socio-demographic, clinic, and therapeutic data were collected.

Results: A total of 505 RA patients were included. Since 2013, the prevalence of monotherapy usage was (any) 49%. The drugs used as monotherapy were Jaki in 41% and TNF-blockers in 30%. The leading causes of monotherapy use were intolerance/adverse events (62%), medical decision or lack of adherence (37.7%). The highest socioeconomic level and a better functional status at diagnosis were predictors of monotherapy use. The use of the second line of treatments and less polypharmacy were independent factors associated with this therapeutic modality.

Conclusions: The current prevalence of monotherapy in RA was 49%, the Jaki were the most used drug in this modality. Monotherapy increases from year to year. There are differential characteristics in patients using monotherapy.

背景:联合治疗是类风湿性关节炎的标准治疗。Jak抑制剂(Jaki)在单药治疗中显示出疗效,单药治疗是在不可能使用改善疾病的抗风湿药物(csDMARDs)的情况下使用的一种方式。目的:估计Jaki上市后bDMARDs或tsDMARDs单药治疗的患病率(总患病率和按药物分类)、使用原因以及随时间的增加。分析单药治疗与联合治疗的差异特点。方法:横断面多中心研究。纳入自2013年开始连续接受bDMARDs或tsDMARDs治疗的RA (ACR/EULAR 2010)患者。收集社会人口学、临床和治疗数据。结果:共纳入505例RA患者。自2013年以来,单一疗法使用率为49%。作为单一疗法使用的药物是Jaki(41%)和tnf受体阻滞剂(30%)。使用单一疗法的主要原因是不耐受/不良事件(62%),医疗决定或缺乏依从性(37.7%)。最高的社会经济水平和诊断时较好的功能状态是单药治疗使用的预测因素。二线治疗的使用和较少的多药治疗是与这种治疗方式相关的独立因素。结论:目前RA单药治疗的患病率为49%,Jaki是该模式中使用最多的药物。单药治疗逐年增加。使用单一疗法的患者有不同的特征。
{"title":"Rheumatoid arthritis monotherapy in the Jak inhibitors Era. Current prevalence and associated factors in a multicenter study.","authors":"Rodrigo Garcia-Salinas,&nbsp;Fernando Sommerfleck,&nbsp;Alfredo Vargas-Caselles,&nbsp;Luis Palomino-Romero,&nbsp;Javier Rosa,&nbsp;Mariana Benegas,&nbsp;Etel Saturansky,&nbsp;Pamela Giorgis,&nbsp;Florencia Martinez,&nbsp;Marcelo Abdala,&nbsp;Jimene Sanchez-Alcover,&nbsp;Emma Civit,&nbsp;Vanesa Espasa,&nbsp;Veronica Bellomio,&nbsp;Juan Manuel Bande,&nbsp;Silvia Papasidero,&nbsp;Veronica Saurit,&nbsp;Leticia Ibañez-Zurlo,&nbsp;Emilio Buschiazzo","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Combined therapy constitutes the standard of care in RA. Jak inhibitors (Jaki) have shown efficacy in monotherapy, a modality used in cases where it is not possible to use Disease-Modifying Anti Rheumatic Drugs (csDMARDs).</p><p><strong>Objectives: </strong>To estimate the prevalence (total and by drug), reason for using and the increase over the time of bDMARDs or tsDMARDs as monotherapy after the availability of the Jaki. To analyze the differential characteristics between patients with monotherapy vs combined therapy.</p><p><strong>Methods: </strong>Cross-sectional multicenter study. Consecutive patients with a diagnosis of RA (ACR/EULAR 2010) under treatment with bDMARDs or tsDMARDs started from 2013 were included. Socio-demographic, clinic, and therapeutic data were collected.</p><p><strong>Results: </strong>A total of 505 RA patients were included. Since 2013, the prevalence of monotherapy usage was (any) 49%. The drugs used as monotherapy were Jaki in 41% and TNF-blockers in 30%. The leading causes of monotherapy use were intolerance/adverse events (62%), medical decision or lack of adherence (37.7%). The highest socioeconomic level and a better functional status at diagnosis were predictors of monotherapy use. The use of the second line of treatments and less polypharmacy were independent factors associated with this therapeutic modality.</p><p><strong>Conclusions: </strong>The current prevalence of monotherapy in RA was 49%, the Jaki were the most used drug in this modality. Monotherapy increases from year to year. There are differential characteristics in patients using monotherapy.</p>","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 1","pages":"41-46"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9564497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complications associated with surgical treatment for pediatric spine deformities: A single center 10-years experience. 小儿脊柱畸形手术治疗的并发症:单中心10年经验。
4区 医学 Q3 RHEUMATOLOGY Pub Date : 2023-01-01
Pedro Fernandes, Isabel Flores, Joaquim Soares do Brito

Introduction: The surgical treatment for pediatric spine deformity is complex and often associated with complications, which generates important clinical and economic impact. Herein the authors analyze the prevalence of complications in surgery for pediatric spine deformity, the correlation between complications and several risk factors, and present a preventive algorithm for these events.

Material and methods: We collected for analysis the data regarding pediatric patients with spine deformities surgically treated in our institution through a 10 years period with 100% revision rate and a 24-month minimum follow-up were included. The statistical analysis was performed using SPSS Statistics 23.

Results: 70 complications (33,4%) were identified in 56 patients (26,7%), of which 38 (54,2%) were acute and 32 (45,7%) late complications. Pulmonary complications (7.1%), surgical site infection (6.6%) and junctional kyphosis (4.3%) were the most frequent events. Scoliosis etiology was especially correlated with general complications (p < 0.05) and early complications (p < 0.01). A logistic regression model identified preoperative hemoglobin (Exp =1.476; P=0.044), fused levels (Exp =-0.677; P=0.023) and titanium implants (Exp =0.257, P < 0.000) as relevant factors for complications. Area under the curve was 0.744, and, when using the best cutting point, the model was capable of predicting absence of complications in 84% of cases, and its occurrence in 56%.

Discussion: Pulmonary complications, surgical site infection and junctional events were identified as the most frequent complications after pediatric scoliosis surgery. By developing high risk protocols to decrease these events, patient safety will be significantly enhanced. Risk assessment makes part of this process and our predictive model by identifying two modifiable factors and including another that relates to procedure invasiveness may help avoiding complications and improve outcomes. ctors for complications. Area under the curve was 0.744, and, when using the best cutting point, the model was capable of predicting absence of complications in 84% of cases, and its occurrence in 56%.

导读:小儿脊柱畸形的手术治疗复杂且常伴有并发症,对临床和经济产生重要影响。本文作者分析了小儿脊柱畸形手术并发症的发生率,并发症与几种危险因素之间的关系,并提出了预防这些事件的算法。材料和方法:我们收集了10年期间在我院手术治疗的脊柱畸形患儿的资料,翻修率为100%,最低随访时间为24个月。采用SPSS Statistics 23进行统计分析。结果:56例(26.7%)患者共发现并发症70例(33.4%),其中急性并发症38例(54.2%),晚期并发症32例(45.7%)。肺部并发症(7.1%)、手术部位感染(6.6%)和关节后凸(4.3%)是最常见的事件。脊柱侧凸病因与一般并发症(p < 0.05)和早期并发症(p < 0.01)相关。logistic回归模型确定术前血红蛋白(Exp =1.476;P=0.044),融合关卡(Exp =-0.677;P=0.023)和钛种植体(Exp =0.257, P < 0.000)是并发症的相关因素。曲线下面积为0.744,当使用最佳切割点时,该模型能够预测84%的病例没有并发症,56%的病例出现并发症。讨论:肺部并发症、手术部位感染和关节事件是小儿脊柱侧凸手术后最常见的并发症。通过制定高风险方案来减少这些事件,将大大提高患者的安全性。风险评估是这个过程和我们的预测模型的一部分,通过确定两个可修改的因素,包括另一个与手术侵入性相关的因素,可以帮助避免并发症和改善结果。治疗并发症。曲线下面积为0.744,当使用最佳切割点时,该模型能够预测84%的病例没有并发症,56%的病例出现并发症。
{"title":"Complications associated with surgical treatment for pediatric spine deformities: A single center 10-years experience.","authors":"Pedro Fernandes,&nbsp;Isabel Flores,&nbsp;Joaquim Soares do Brito","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>The surgical treatment for pediatric spine deformity is complex and often associated with complications, which generates important clinical and economic impact. Herein the authors analyze the prevalence of complications in surgery for pediatric spine deformity, the correlation between complications and several risk factors, and present a preventive algorithm for these events.</p><p><strong>Material and methods: </strong>We collected for analysis the data regarding pediatric patients with spine deformities surgically treated in our institution through a 10 years period with 100% revision rate and a 24-month minimum follow-up were included. The statistical analysis was performed using SPSS Statistics 23.</p><p><strong>Results: </strong>70 complications (33,4%) were identified in 56 patients (26,7%), of which 38 (54,2%) were acute and 32 (45,7%) late complications. Pulmonary complications (7.1%), surgical site infection (6.6%) and junctional kyphosis (4.3%) were the most frequent events. Scoliosis etiology was especially correlated with general complications (p < 0.05) and early complications (p < 0.01). A logistic regression model identified preoperative hemoglobin (Exp =1.476; P=0.044), fused levels (Exp =-0.677; P=0.023) and titanium implants (Exp =0.257, P < 0.000) as relevant factors for complications. Area under the curve was 0.744, and, when using the best cutting point, the model was capable of predicting absence of complications in 84% of cases, and its occurrence in 56%.</p><p><strong>Discussion: </strong>Pulmonary complications, surgical site infection and junctional events were identified as the most frequent complications after pediatric scoliosis surgery. By developing high risk protocols to decrease these events, patient safety will be significantly enhanced. Risk assessment makes part of this process and our predictive model by identifying two modifiable factors and including another that relates to procedure invasiveness may help avoiding complications and improve outcomes. ctors for complications. Area under the curve was 0.744, and, when using the best cutting point, the model was capable of predicting absence of complications in 84% of cases, and its occurrence in 56%.</p>","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 1","pages":"22-29"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9617280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of intra-articular glucocorticoid injections - state of the art. 关节内糖皮质激素注射的安全性——最新进展。
4区 医学 Q3 RHEUMATOLOGY Pub Date : 2023-01-01
Ana Margarida Duarte-Monteiro, Eduardo Dourado, João E Fonseca, Fernando Saraiva

Intra-articular glucocorticoid injection (IAGCI) is frequently used to treat joint pain and inflammation. While its efficacy has been extensively studied, there are not as many detailed descriptions regarding safety. This review aimed to describe the immediate-, short- and long-term complications of IAGCI and their predictors. Most studies mainly report mild and self-limited adverse events with an incidence similar to placebo. However, the reported incidences vary significantly and are mostly inferred from retrospective data. Septic arthritis is the most feared adverse event due to its association with high mortality. Other short-term local complications include injection site pain, post-injection flare, skin hypopigmentation and atrophy, and tendon rupture. Systemic side effects are common, including vasovagal reactions, flushing, increased appetite and mood changes, hyperglycemia in diabetic patients, and bleeding in high-risk patients. Few predictors of complications have been systematically evaluated. However, male gender, advanced age, and pre-existing joint disease have been suggested in retrospective studies to correlate with infection risk. Overall, in most studies, only severe adverse event rates are reported, with no systematic prospective evaluations of safety and no report of predictors of complications. Therefore, since IAGCI is a routinely used treatment, more detailed knowledge of adverse events and complications is warranted.

关节内糖皮质激素注射(IAGCI)常用于治疗关节疼痛和炎症。虽然对其功效进行了广泛的研究,但对其安全性的详细描述并不多。本综述旨在描述IAGCI的即时、短期和长期并发症及其预测因素。大多数研究主要报告轻度和自限性不良事件,发生率与安慰剂相似。然而,报告的发病率差异很大,而且大多是从回顾性数据推断出来的。脓毒性关节炎是最可怕的不良事件,因为它与高死亡率有关。其他短期局部并发症包括注射部位疼痛、注射后耀斑、皮肤色素减退和萎缩以及肌腱断裂。全身副作用是常见的,包括血管迷走神经反应、潮红、食欲增加和情绪变化、糖尿病患者高血糖和高危患者出血。很少有并发症的预测因素被系统地评估过。然而,回顾性研究表明,男性、高龄和先前存在的关节疾病与感染风险相关。总的来说,在大多数研究中,只报告了严重的不良事件发生率,没有系统的安全性前瞻性评估,也没有并发症预测因素的报告。因此,由于IAGCI是常规使用的治疗方法,因此有必要更详细地了解不良事件和并发症。
{"title":"Safety of intra-articular glucocorticoid injections - state of the art.","authors":"Ana Margarida Duarte-Monteiro,&nbsp;Eduardo Dourado,&nbsp;João E Fonseca,&nbsp;Fernando Saraiva","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Intra-articular glucocorticoid injection (IAGCI) is frequently used to treat joint pain and inflammation. While its efficacy has been extensively studied, there are not as many detailed descriptions regarding safety. This review aimed to describe the immediate-, short- and long-term complications of IAGCI and their predictors. Most studies mainly report mild and self-limited adverse events with an incidence similar to placebo. However, the reported incidences vary significantly and are mostly inferred from retrospective data. Septic arthritis is the most feared adverse event due to its association with high mortality. Other short-term local complications include injection site pain, post-injection flare, skin hypopigmentation and atrophy, and tendon rupture. Systemic side effects are common, including vasovagal reactions, flushing, increased appetite and mood changes, hyperglycemia in diabetic patients, and bleeding in high-risk patients. Few predictors of complications have been systematically evaluated. However, male gender, advanced age, and pre-existing joint disease have been suggested in retrospective studies to correlate with infection risk. Overall, in most studies, only severe adverse event rates are reported, with no systematic prospective evaluations of safety and no report of predictors of complications. Therefore, since IAGCI is a routinely used treatment, more detailed knowledge of adverse events and complications is warranted.</p>","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 1","pages":"64-73"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9661854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
ARP Rheumatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1